New York has filed a lawsuit against pharmaceutical giant Actavis over allegations of an anticompetitive moves to block generic competition that forced consumers to pay higher prices for an Alzheimer’s drug, according to reports.
NY Attorney General Eric Schneiderman filed a complaint against the Irish company on Monday that accuses the company of swapping out one version of its Namenda drug for another that had a longer period of time until its patent expired.
That plan, AG Schneiderman said, was aimed at blocking its generic rival from entering the market and violates both state and federal antitrust law.
”We’re sending a clear message to all pharmaceutical companies: Prioritizing profits over patients’ rights will not be tolerated,” the official said in a statement.
According to complaints, Actavis is discontinuing its Namenda drug to release a slow-release version of the same medication; Namenda’s patent is set to expire in October of next year.
The tactic is sometimes known as a “forced switch” that forces patients to switch medication, which delays entry of generic competition into the market.
Actavis did not immediately respond to requests for comment, reports said.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UFC Reaches $375 Million Settlement in Antitrust Case
Feb 6, 2025 by
CPI
Brazilian Architecture Council Convicted of Antitrust Violations
Feb 6, 2025 by
CPI
Bipartisan Bill Seeks to Ban Chinese AI Software from US Government Devices
Feb 6, 2025 by
CPI
Senators Call for Investigation into RealPage Algorithm’s Impact on Military Housing Costs
Feb 6, 2025 by
CPI
ECB Seeks Faster Digital Euro Legislation Amid US Stablecoin Push
Feb 6, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon